Exhibit 10.68


SECURITIES PURCHASE
AGREEMENT


THIS SECURITIES
PURCHASE AGREEMENT (the ''Agreement”) is entered into by and among Zander Therapeutics, Inc., a Nevada corporation (the (“Company'')
whose address is


Brian Devine (


Person whose address is
_____________


WHEREAS:


The Purchaser desires
to purchase shares of the common stock of the Company ('Shares'') in


accordance with the terms
and conditions set forth herein.


The Company desires
to issue and sell Shares to the Purchaser in accordance with the terms and


conditions set forth herein.


THEREFORE, IT IS AGREED
AS FOLLOWS


	 	1.	Purchase Price 


The purchase price
per Share ("Purchase Price"), payable in US Dollars, shall be $1 per Share.


	 	2.	Form of Payment


The Purchaser shall pay
the Purchase Prjce per Share multiplied by that number of Shares


Purchased by wire transfer
of immediately available funds to the Company on or prior to 6/23/2017


 


WIRE INSTRUCTIONS:


Zander Therapeutics
Wire Instructions:


 


	 	1	 




    	 



    	 



    

 


 


	 	3.	Issuance of Stock


5 business days
subsequent to receipt of payment of the Purchase Price the Company shall issue


to the Purchaser that number
of Shares purchased


	 	4.	Purchaser's Representations and Warranties


 


	 	(a)	As of the date hereto the Purchaser is purchasing the Shares for its own account and not with a present view towards the public sale or distribution thereof, except pursuant to sales registered or exempted from registration under the Securities Act of 1933, as amended (the ''Act'').


 


	 	(b)	The Purchaser is an "accredited investor', as that term is defined in Rule 501(a) of


Regulation D promulgated
under the Act


	 	(c)	The Purchaser and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Stocks which have been requested by the Purchaser or its advisors. Notwithstanding the foregoing, the Company has not disclosed to the Purchaser any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to such disclosure to the Purchaser.


 


	 	(d)	Purchaser has the requisite power and authority to enter into and perform its obligations under this Agreement without the consent, approval or authorization ot or obligation to notify, any person, entity or governmental agency which consent has not been obtained.


 


	 	(e)	The execution delivery and performance of this Agreement by Purchaser does not and shall not constitute Purchaser's breach of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions, or provisions of any order, writ, injunctiot1t decree, contract, agreement, or instrument to which the Purchaser is a party, or by which Purchaser is or may be bound.


5. Company's representations
and warranties


(a) 
Company is a corporation duly organized, validly existing and in good standing under the laws of the state its incorporation
and has the requisite corporate power and authority to enter into and perform its obligations under this Agreement without the
consent approval or authorization of or obligation to notify any person, entity or governmental agency which consent has not been
obtained.


(b)  
The execution, delivery and performance of this Agreement by Company does not and shall not constitute Company's breach
of any statute or regulation or ordinance of any governmental authority, and shall not conflict with or result in a breach of or
default under


	 	2	 




    	 



    	 



    

 


 


any
of the terms, conditions, or provisions of any order, writ, injunction, decree, contract, agreement, or instrument to which the
Company is a partyt Ot" by which Company is or may be bound.


6. Restricted Securities
Acknowledgement


Purchaser
acknowledges that any securities issued pursuant to this Agreement that shall not be registered pursuant to the Securities Act
of 1933 sha11 constitute "restricted securities" as that term is defined in Rule 144 promulgated under the Act, and shall
contain the following restrictive legend:


'"IHESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIESACT OF 1933, AS AMENDED (THE "ACT''), OR SECURITIES LAws OF ANY STATE
AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE-OF AN EFEBCTIVE REGISTRATION
STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE
ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY
THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS."


7. Entire Agreement


This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.


8. Governing Law, Venue, Waiver Of Jury
Trial


All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient venue for such
proceeding. If either party shall commence an action or proceeding to enforce any provisions of this Agreement, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its attorneys' fees and other costs and expenses
incurred with the investigation, preparation and prosecution of such action or proceeding.


	 	3	 




    	 



    	 



    

 


 


IN WITNESS WHEREOF, the parties
have hereunto executed this Agreement on the 20th Day of June 2017


 


Zander Therapeutics, Inc


/s/David Koos


David Koos , CEO


6.20.2017


 


Purchaser


By:/s/Brian Devine


6/20/2017


Number of Shares of Common
Stock Purchased $100,000


Total Purchase Price: $100,000